Monthly Archives: June 2021

Second report of trans man undergoing successful fertility preservation without stopping testosterone – this time producing a viable embryo and live birth

Posted on June 30, 2021 by Zinnia Jones

Previously: Update on ovarian stimulation after testosterone use: Successful fertility preservation with less than a month’s interruption of HRT (April 2020) First report of trans man having successful fertility preservation without interrupting HRT (February 2021) Over the past few years, … Continue reading →

Posted in Biology of transition, Endocrinology, Fertility and reproduction, Transmasculine | Tagged , , | Leave a comment

Additional data confirms 10mg of cyproterone acetate (CPA) is effective for testosterone suppression in trans women

Posted on June 30, 2021 by Zinnia Jones

Previously: Lower doses of cyproterone acetate may be similarly effective for blocking testosterone, with a lower risk of adverse effects (August 2020) Study of entire French population offers further data on cyproterone acetate and meningioma risk (February 2021) Disclaimer: I … Continue reading →

Posted in Antiandrogens, Endocrinology, Oncology, Progestogens, Transgender medicine | Tagged , , | Leave a comment

Three decades and hundreds of transfeminine breast augmentations show rare regret and trends toward larger implants

Posted on June 1, 2021 by Zinnia Jones

Trans women and transfeminine people seeking breast augmentation as part of medical transition face certain concerns distinct from cis women who may receive this surgery. Our anatomical baseline is very different from that of adult cis women, with a recent … Continue reading →

Posted in Breast, Oncology, Outcomes of transition, Surgery, Transfeminine, Transgender medicine | Tagged , | Leave a comment